

IPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Yosef SHAUL et al

Serial No.: 10/759,037

Filed: January 20, 2004

For: Hepatitis B Virus Binding Proteins  
and Uses Thereof

Examiner:

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450



§  
§  
§  
§  
§  
§  
§  
§  
§  
§

Group Art Unit: 1648

Attorney  
Docket: 27169

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

Applicant requests that MPEP 609 be complied with and the examiner consider information which has been considered by the Office in a parent application when examining (A) a continuation application, (B) a divisional application, or (C) a continuation-in-part application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

  
Sol Sheinbein

Registration No. 25,457

Date: June 14, 2004

Please type a plus sign (+) inside this box → ☒

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/759,037
Filing Date	01/20/2004
First Named Inventor	Shaul
Group Art Unit	1648
Examiner Name	
Attorney Docket Number	27169

Sheet	1	Of	1
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Davis, CG, "The many faces of epidermal growth factor repeats", <i>New Biol.</i> 1990 May;2(5):410-9.	
		DeMeyer et al, "Organ and Species Specificity of Hepatitis B Virus (HBV) Infection: A Review of Literature with a Special Reference to Preferential Attachment of HBV to Human Hepatocytes", <i>J. Viral Hepatitis</i> , 4:145-153, 1997	
		Doolittle et al, "Computer-based characterization of epidermal growth factor precursor", <i>Nature</i> . 1984 Feb 9-15;307(5951):558-60.	
		Lecka-Czernik et al, "An overexpressed gene transcript in senescent and quiescent human fibroblasts encoding a novel protein in the epidermal growth factor-like repeat family stimulates DNA synthesis", <i>Mol Cell Biol.</i> 1995 Jan;15(1):120-8.	
		Neurath et al, "Hepatitis B virus contains pre-S gene-encoded domains", <i>Nature</i> . 1985 May 9-15;315(6015):154-6.	
		Neurath et al, "Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing", <i>Vaccine</i> . 1986 Mar;4(1):35-7.	
		Petit et al, "HepG2 cell binding activities of different hepatitis B virus isolates: inhibitory effect of anti-HBs and anti-preS1(21-47)", <i>Virology</i> . 1991 Feb;180(2):483-91.	
		Shouval et al, "Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines", <i>Vaccine</i> . 1994 Nov;12(15):1453-9.	
Examiner Signature			Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>. Unique citation designation number. <sup>2</sup>. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.